Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
At 10 nM, SR-31747 inhibits the growth of lymphocytes. Twenty-four hours after activation, SR-31747 is administered, and this decreases T cell growth. SR-31747 inhibits the growth of yeast cells in a manner that is dependent on dosage [2].
|
---|---|
ln Vivo |
SR-31747 exhibited a dose-dependent inhibition of lipopolysaccharide-induced IL-1, IL-6, and TNF-α production in vivo (ED50 = 2 mg/kg). Monokine synthesis is inhibited by SR-31747, potentially by a secondary mechanism involving endogenous corticosteroids. In vivo tests that demonstrate that: 1) SR-31747 treatment causes raised corticosterone levels; and 2) corticosteroid removal via mifepristone or adrenalectomy reduces the effects of SR-31747 support this result. By single-factor inhibition, SR-31747 increases the survival of mice that have been exposed to endotoxins [1].
|
References |
|
Additional Infomation |
Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities.
Drug Indication Investigated for use/treatment in cancer/tumors (unspecified), immunosuppressive, and prostate cancer. Mechanism of Action SR31747 blocks proliferation of human lymphocytes, modulates the expression of pro- and anti-inflammatory cytokines, and was shown to protect animals in vivo against acute and chronic inflammatory conditions such as acute graft-versus-host reaction, lethality induced by staphylococcal enterotoxin B and lipopolysaccharide or rheumatoid arthritis. Besides these immunomodulatory activities, the molecule also inhibits the proliferation of various tumor cell lines in vitro in a time- and concentration-dependent manner. |
Molecular Formula |
C23H34NCL.HCL
|
---|---|
Molecular Weight |
396.4367
|
Exact Mass |
395.215
|
CAS # |
132173-07-0
|
Related CAS # |
SR-31747 free base;132173-06-9
|
PubChem CID |
6439330
|
Appearance |
White to off-white solid powder
|
Boiling Point |
479.9ºC at 760 mmHg
|
Flash Point |
244.1ºC
|
Vapour Pressure |
2.26E-09mmHg at 25°C
|
LogP |
7.857
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
1
|
Rotatable Bond Count |
6
|
Heavy Atom Count |
26
|
Complexity |
395
|
Defined Atom Stereocenter Count |
0
|
SMILES |
CCN(C/C=C\C1=CC(=C(C=C1)C2CCCCC2)Cl)C3CCCCC3.Cl
|
InChi Key |
HKHPCMBPASXYGP-KVVVOXFISA-N
|
InChi Code |
InChI=1S/C23H34ClN.ClH/c1-2-25(21-13-7-4-8-14-21)17-9-10-19-15-16-22(23(24)18-19)20-11-5-3-6-12-20;/h9-10,15-16,18,20-21H,2-8,11-14,17H2,1H3;1H/b10-9-;
|
Chemical Name |
N-[(Z)-3-(3-chloro-4-cyclohexylphenyl)prop-2-enyl]-N-ethylcyclohexanamine;hydrochloride
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~15.62 mg/mL (~39.40 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.56 mg/mL (3.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 15.6 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.56 mg/mL (3.94 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 15.6 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.56 mg/mL (3.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5224 mL | 12.6122 mL | 25.2245 mL | |
5 mM | 0.5045 mL | 2.5224 mL | 5.0449 mL | |
10 mM | 0.2522 mL | 1.2612 mL | 2.5224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.